Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

LY2334737

Catalog No: tcsc1815

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Specifications

CAS No:
892128-60-8

Formula:
$C_{17}H_{25}F_2N_3O_5$

Pathway:
Cell Cycle/DNA Damage

Target:
Nucleoside Antimetabolite/Analog

Purity / Grade:
>98%

Solubility:
10 mM in DMSO

Observed Molecular Weight:
389.39

Product Description

LY2334737 is an orally available prodrug of gemcitabine which is a nucleoside analog used as chemotherapy.

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

IC50 Value:

Target: Nucleoside analog

in vitro: Five cell lines that express CES2 responded to LY2334737treatment. LY2334737 was less cytotoxic to a SK-OV-3 CES2 knockdown than parental cells. The drug response of CES2-transfected HCT-116 cells correlated with CES2 expression level. Bystander studies showed statistically greater PC-3-GFP growth inhibition by LY2334737 when cells were cocultured with CES2 and not mock transfectants [1].

in vivo: Oral treatment of xenograft models with 3.2 mg/kg LY2334737 once a day for 21 days showed greater tumor growth inhibition of CES2 transfectant than the mock transfectant ($P \leq 0.001$) [1]. The MTD was 40 mg LY2334737. Fatigue was the most frequent DLT for LY2334737monotherapy (4 patients) followed by elevated transaminase levels (2 patients), both observed at the 40- to 50-mg dose levels. Among the 10 patients in the combination arm, 2 had DLTs at the 40-mg dose level. These were fatigue and elevated liver enzyme levels [2]. Metronomic LY2334737 administration caused increased blood flow in luciferase-tagged LM2-4 tumor xenografts, and this effect, readily measured using contrast micro-ultrasound, coincided with a relative increase in tumor bioluminescence [3].